These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37822267)

  • 41. Current pharmacotherapies of alcoholism: a U.S. perspective.
    Anton RF; Swift RM
    Am J Addict; 2003; 12(s1):s53-s68. PubMed ID: 14972780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient Perspectives on Pharmacotherapy of Alcohol Dependence.
    Wellensiek J; Specka M; Just J; Banger M; Bonnet U; Scherbaum N
    Pharmacopsychiatry; 2024 Jan; 57(1):21-29. PubMed ID: 38052239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medical treatment of alcohol dependence: a systematic review.
    Miller PM; Book SW; Stewart SH
    Int J Psychiatry Med; 2011; 42(3):227-66. PubMed ID: 22439295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review.
    Zakiyah N; Marulin D; Alfaqeeh M; Puspitasari IM; Lestari K; Lim KK; Fox-Rushby J
    J Med Internet Res; 2024 Apr; 26():e53500. PubMed ID: 38687991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder.
    Belnap MA; McManus KR; Grodin EN; Ray LA
    Pharmaceut Med; 2024 Jul; 38(4):291-302. PubMed ID: 38967906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking.
    González-Marín MC; Lebourgeois S; Jeanblanc J; Diouf M; Naassila M
    Neuropharmacology; 2018 Sep; 140():14-24. PubMed ID: 30031019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
    Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
    Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations.
    Yang F; Liao M; Wang P; Yang Z; Liu Y
    Appl Health Econ Health Policy; 2021 Mar; 19(2):163-180. PubMed ID: 33047212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Castrén S; Mäkelä N; Alho H
    Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2000; (3):CD001867. PubMed ID: 10908513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combining psychosocial treatment with pharmacotherapy for alcohol dependence.
    Weiss RD; Kueppenbender KD
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S37-42. PubMed ID: 17114954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
    Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
    Drug Alcohol Depend; 2016 Sep; 166():254-7. PubMed ID: 27394934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
    Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
    Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
    Kranzler HR; Soyka M
    JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
    Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
    Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
    Hulin MW; Lawrence MN; Amato RJ; Weed PF; Winsauer PJ
    Alcohol; 2015 Mar; 49(2):127-38. PubMed ID: 25620274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors of long-term follow-up in treatment of Korean alcoholics with naltrexone or acamprosate.
    Huh SY; Kim SG; Hong TK
    Int Clin Psychopharmacol; 2020 Nov; 35(6):345-350. PubMed ID: 32784347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which interventions for alcohol use should be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence.
    Botwright S; Sutawong J; Kingkaew P; Anothaisintawee T; Dabak SV; Suwanpanich C; Promchit N; Kampang R; Isaranuwatchai W
    BMC Public Health; 2023 Feb; 23(1):382. PubMed ID: 36823618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.